<SEC-DOCUMENT>9999999995-25-002673.txt : 20250820
<SEC-HEADER>9999999995-25-002673.hdr.sgml : 20250820
<ACCEPTANCE-DATETIME>20250820001509
ACCESSION NUMBER:		9999999995-25-002673
CONFORMED SUBMISSION TYPE:	EFFECT
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250819
DATE AS OF CHANGE:		20250820
EFFECTIVENESS DATE:		20250819

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BridgeBio Oncology Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001869105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		EFFECT
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288222
		FILM NUMBER:		251233714

	BUSINESS ADDRESS:	
		STREET 1:		256 E. GRAND AVENUE, SUITE 104
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		857 702 0377

	MAIL ADDRESS:	
		STREET 1:		256 E. GRAND AVENUE, SUITE 104
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Helix Acquisition Corp. II
		DATE OF NAME CHANGE:	20210623
</SEC-HEADER>
<DOCUMENT>
<TYPE>EFFECT
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<edgarSubmission>

    <schemaVersion>X0101</schemaVersion>

    <submissionType>EFFECT</submissionType>

    <act>33</act>

    <testOrLive>LIVE</testOrLive>

    <effectiveData>
        <finalEffectivenessDispDate>2025-08-19</finalEffectivenessDispDate>
        <accessionNumber>0001213900-25-076945</accessionNumber>
        <submissionType>POS AM</submissionType>
        <filer>
            <cik>0001869105</cik>
            <entityName>BridgeBio Oncology Therapeutics, Inc.</entityName>
            <fileNumber>333-288222</fileNumber>
        </filer>
    </effectiveData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
